Solasia Pharma K.K. (4597)
Market Closed
12 Aug, 06:00
JPX JPX Primary ¥
30. 00
-1
-3.2258%
¥
8.69B Market Cap
- P/E Ratio
- Div Yield
73.02M Volume
- Eps
¥ 31
Previous Close Want to track 4597 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
4597 closed today lower at ¥30, a decrease of -3.2258% from yesterday's close, completing a monthly increase of 20% or ¥5. Over the past 12 months, 4597 stock gained 3.4483%.
4597 is not paying dividends to its shareholders.
The last earnings report, released on May 20, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
4597 Chart
Solasia Pharma K.K. (4597) FAQ
What is the stock price today?
The current price is ¥30.00.
On which exchange is it traded?
Solasia Pharma K.K. is listed on JPX.
What is its stock symbol?
The ticker symbol is 4597.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 8.69B.
Has Solasia Pharma K.K. ever had a stock split?
No, there has never been a stock split.
Solasia Pharma K.K. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yoshihiro Arai CEO | JPX Exchange | JP3436500007 ISIN |
| Japan Country | 22 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Solasia Pharma K.K. is a pharmaceutical company primarily focused on oncology, offering an array of drugs for managing side effects associated with cancer treatments. Established in 2006, the company aims to address the needs of cancer patients in Japan and across other Asian countries by developing and marketing specialized pharmaceutical products. With a keen focus on improving the quality of life for individuals undergoing chemotherapy and radiotherapy, Solasia Pharma has positioned itself as a key player in the Asian oncology pharmaceutical market.
Products and Services
- episil oral liquid - A specially formulated oral liquid designed to protect against and alleviate oral pain. This pain is often a consequence of oral mucositis or stomatitis, painful conditions frequently brought on by chemotherapy and radiotherapy treatments for cancer. By addressing these oral complications, episil aims to provide significant relief and improve the quality of life for cancer patients undergoing intense treatment regimes.
- Sancuso - This product represents a pioneering approach in the management of chemotherapy-induced nausea and vomiting, a common and debilitating side effect of cancer treatment. Sancuso utilizes a transdermal delivery system to administer granisetron, an anti-emetic agent, directly into the bloodstream. This method of delivery ensures sustained relief from nausea and vomiting, enabling patients to better tolerate their chemotherapy cycles.
- Darvias injection - As an antineoplastic agent and organic arsenic product, Darvias injection is specifically indicated for use in patients with relapsed or refractory peripheral T-cell lymphoma. This treatment offers hope to those with this challenging form of cancer, providing a targeted therapeutic option when other treatments have failed.
- SP-04 - Currently in the pre-clinical stage of development, SP-04 is a promising new treatment aimed at combating chemotherapy-induced peripheral neuropathy, a serious and often debilitating condition affecting cancer patients. By focusing on this unmet medical need, Solasia Pharma underscores its commitment to expanding its portfolio towards addressing a wider range of the side effects associated with cancer therapy.
Contact Information
Address: Sumitomo Fudosan Shiba-Koen Tower
Phone: 81 3 5843 8046
Website: https://www.solasia.co.jp
